Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Launched by WONJU SEVERANCE CHRISTIAN HOSPITAL · Jan 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different medications, dapagliflozin and gemigliptin, on heart health and fat metabolism in people with type 2 diabetes. Researchers want to see if dapagliflozin, which is part of a group of drugs called SGLT2 inhibitors, can improve how the body processes certain fats called ketones compared to gemigliptin, which is a different type of diabetes medication. The study will involve 122 participants who will be given one of the two medications for six months. Doctors will monitor changes in heart function and fat metabolism using various tests.

To join the study, participants must have a stable diagnosis of type 2 diabetes and not have taken any SGLT2 inhibitors in the last three months. Some people may not qualify if their blood sugar levels are too high, they are pregnant or breastfeeding, or if they use insulin. Those who participate can expect regular check-ups and tests to track their health over the study period. This research aims to better understand how these medications can help protect heart health in people with diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects diagnosed with T2D on stable antidiabetic medication
• • No recent use of SGLT2 inhibitor within 3 months
• Exclusion Criteria:
• • HbA1c \> 10%
• • Pregnancy or breast feeding
• • estimated GFR \<45 30 mL/min/1.73㎡
• • insulin user